微通道经皮肾镜在上尿路结石合并糖尿病患者中的应用

目的探讨微通道经皮肾镜碎石取石术（MPCNL）治疗合并糖尿病的上尿路结石患者的安全性和疗效。 方法回顾性分析2011年10月到2015年9月罗定市人民医院行MPCNL的83例患有糖尿病的上尿路结石患者的病例资料，并选择83例同期行MPCNL的非糖尿病患者，比较两组患者术前的一般情况、手术时间、出血量、结石清除率、住院时间、并发症等。 结果两组患者年龄、性别、体质量指数、结石大小等一般情况比较差异无统计学意义（P>0.05），糖尿病组患者与非糖尿病组患者在手术时间（82±29） min vs（77±30） min，P=0.306]、血红蛋白下降（1.8±0.7）g/L vs（1.7±0.6）g/L，P=0.325]、全身炎症反应综合征（SIRS）发生率（26.5% vs 22.9%，P=0.719）、结石清除率（92.8% vs 95.2%，P=0.746）、住院时间（11.2±2.3）d vs（10.8±2.1）d，P=0.244]等方面差异均无统计学意义。 结论MPCNL治疗上尿路结石伴有糖尿病的患者时，出血与感染风险与非糖尿病患者相比无明显差异，是一种安全有效的治疗手段。

Micro channel percutaneous nephrolithotripsy in treating upper ureteral calculi complicated with diabetes

ObjectiveTo assess the efficacy and safety of micro channel percutaneous nephrolithotripsy (MPCNL) for upper ureteral calculi in patients with diabetes. MethodsRetrospective investigation was performed on 166 cases of upper ureteral calculi patients who had underwent MPCNL from October 2011 to September 2015 in Luoding People's Hospital, 83 cases of the patients were complicated with diabetes (Diabetes group) and the others without diabetes (Control group). ResultsThere was no statistical difference between the two groups in age, gender, body mass index (BMI), stone size and position (all P>0.05). There was no significant difference between Diabetes group and Control group in operation time (82.1±28.8) min vs (77.4±30.2) min, P=0.306], decrease of hemoglobin (1.8±0.7) g/Lvs (1.7±0.6) g/L, P=0.325], systemic inflammatory response syndrome (26.5% vs 22.9%, P=0.719), stone-free rate(92.8% vs 95.2%, P=0.746), hospital stays (11.2±2.3) d vs (10.8±2.1) d, P=0.244]. ConclusionMicro channel percutaneous nephrolithotripsy is a safe and effective therapy in treating upper ureteral calculi complicated with diabetes.